Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
KOREA E & EX
RG Advertising

Red Reflex Test Helps Rule Out Retinoblastoma

By HospiMedica International staff writers
Posted on 04 Jun 2014
Image: The CHECT Red Reflex Poster – link provided below (Photo courtesy of CHECT).
Image: The CHECT Red Reflex Poster – link provided below (Photo courtesy of CHECT).
General Practitioners (GPs) in the United Kingdom are being urged to ensure every squint is checked to rule out eye cancer.

The Childhood Eye Cancer Trust (CHECT; London, United Kingdom) is urging that all squints in babies and young children be checked with a red reflex test to exclude a diagnosis of retinoblastoma (Rb). As squints are common in babies up to the age of three months, the only way to determine whether this is a sign of a much more serious condition is to carry out the test, a noninvasive procedure that involves looking in the eye with a hand-held ophthalmoscope.

To promote this message, CHECT has developed e-cards and an email campaign that GPs can share and forward on to colleagues. The campaign asks that particular attention be paid to children with a recently onset squint; a white pupillary reflex (leukocoria); an abnormal reflex in photographs taken with a flash; a change in color of the iris; or a deterioration in vision. According to figures released by CHECT, 26% of babies and young children diagnosed with Rb presented with a squint, which is the second most common symptom of the disease (after leukocoria).

“In our experience, some babies and young children are facing serious delays in receiving life-saving treatment as a result of parents either being told incorrectly that their baby's squint is completely normal, or being given a non-urgent squint referral,” said Joy Felgate, CEO of CHECT. “If you are unable to confidently rule out retinoblastoma with a red reflex test, NICE guidelines state an urgent referral must be made to the local ophthalmology department stating 'suspected retinoblastoma.'”

Retinoblastoma is a fast-growing cancer that develops from the immature cells of a retina, affecting mainly children up to five years of age. Early detection of this aggressive condition is crucial to offer the child the best chance of saving their vision, their eyes, and their life. There are two forms of the disease, a heritable form and nonheritable form; about 55% of children with Rb have the nonheritable form. In about two thirds of cases, only one eye is affected (unilateral retinoblastoma); in the other third, tumors develop in both eyes.

Related Links:

Childhood Eye Cancer Trust
CHECT Red Reflex Poster



Channels

Surgical Techniques

view channel

Raman Scattering Helps Evaluate Laser Ablation

Raman spectroscopy can be used to differentiate squamous cell carcinoma (SCC) from normal skin following treatment with high-powered lasers, according to a new study. Researchers at Florida Atlantic University (FAU; Boca Raton, USA) obtained 25 tissue samples from 11 patients undergoing Mohs micrographic surgery for... Read more

Women's Health

view channel

Nitrous Oxide for Labor Makes US Comeback

Long used for its anxiolytic properties during labor in European countries and Canada, nitrous oxide (N2O) use is resurging in the United States. While in countries such as Norway, New Zealand, Sweden, Australia, and England, usage rates of inhalational N2O during parturition reach 70%, it has only recently become an... Read more

Health IT

view channel
Image: Remote Intelligent Telehealth Assistant (RITA) (Photo courtesy of PR Newswire).

Telehealth Robot Launched to Increase Productivity of Doctors in Clinics and Hospitals

A robot uses high-definition monitors, high-speed components, and wireless communications, and serves as a telehealth media center to give doctors more flexibility in treating and assisting patients remotely.... Read more

Business

view channel

Pfizer to Buy Hospira to Bolster Hospital Products

Pfizer (New York, NY, USA) has entered into a definitive merger agreement with Hospira (Lake Forest, IL, USA), in a move designed to significantly enhance their global established pharmaceutical (GEP) business, for a total enterprise value of approximately USD 17 billion. The strategic complementary combination will... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.